Lexaria Bioscience Corp. (LXRP) financial statements (2021 and earlier)

Company profile

Business Address 100 - 740 MCCURDY ROAD
KELOWNA, BC V1X 2P7
State of Incorp. NV
Fiscal Year End August 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

11/30/2020
Q1
8/31/2020
Q4
5/31/2020
Q3
2/29/2020
Q2
11/30/2019
Q1
8/31/2019
Q4
5/31/2019
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments5691,3132,0527641,3561,3492,071
Cash and cash equivalents5251,2942,0347401,3331,2851,996
Short-term investments44191824236475
Receivables427314254227326273226
Inventory, net of allowances, customer advances and progress billings126117133124134127188
Inventory126117133124134127188
Prepaid expense13618289659669123
Disposal group, including discontinued operation49      
Total current assets:1,3081,9262,5281,1801,9111,8192,608
Noncurrent Assets
Operating lease, right-of-use asset118127     
Property, plant and equipment452483511538565591607
Intangible assets, net (including goodwill)296292281268269265243
Intangible assets, net (excluding goodwill)296292281268269265243
Total noncurrent assets:867902792806835856849
TOTAL ASSETS:2,1742,8283,3201,9862,7462,6753,457
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:8387556293136111
Accounts payable      87
Taxes payable      19
Other undisclosed accounts payable and accrued liabilities83875562931365
Due to related parties8759302374821
Other undisclosed current liabilities72806    
Total current liabilities:2422269163130185132
Noncurrent Liabilities
Long-term debt and lease obligation8089     
Operating lease, liability8089     
Other undisclosed noncurrent liabilities(49)3129    
Total noncurrent liabilities:11112029    
Total liabilities:35334612063130185132
Stockholders' equity
Stockholders' equity attributable to parent, including:1,8782,5253,1871,8802,6162,3833,325
Common stock3909081817978
Additional paid in capital30,37330,23730,18427,52527,22126,17225,891
Accumulated deficit(28,498)(27,802)(27,087)(25,726)(24,776)(23,868)(22,790)
Other undisclosed stockholders' equity attributable to parent    90 145
Stockholders' equity attributable to noncontrolling interest(57)(43)1443 108145
Other undisclosed stockholders' equity    (90) (291)
Total stockholders' equity:1,8212,4823,2011,9232,5262,4913,179
Other undisclosed liabilities and equity    90 145
TOTAL LIABILITIES AND EQUITY:2,1742,8283,3201,9862,7462,6753,457

Income statement (P&L) ($ in thousands)

11/30/2020
Q1
8/31/2020
Q4
5/31/2020
Q3
2/29/2020
Q2
11/30/2019
Q1
8/31/2019
Q4
5/31/2019
Q3
Revenues296134811076212560
Cost of revenue
(Cost of Goods and Services Sold)
(64)(13)(20)(58)(8)(15)(3)
Gross profit:23112161495411057
Operating expenses(944)(892)(1,452)(1,047)(979)(1,226)(1,245)
Operating loss:(713)(772)(1,391)(997)(925)(1,116)(1,188)
Other undisclosed income from continuing operations before equity method investments, income taxes 98     
Loss from continuing operations before income taxes:(713)(674)(1,391)(997)(925)(1,116)(1,188)
Other undisclosed loss from continuing operations (2)     
Loss from continuing operations:(713)(676)(1,391)(997)(925)(1,116)(1,188)
Income from discontinued operations3      
Net loss:(710)(676)(1,391)(997)(925)(1,116)(1,188)
Net income attributable to noncontrolling interest 572947   
Other undisclosed net loss attributable to parent (152)     
Net loss attributable to parent:(710)(772)(1,361)(950)(925)(1,116)(1,188)
Other undisclosed net income available to common stockholders, basic1457  173811
Net loss available to common stockholders, diluted:(696)(715)(1,361)(950)(907)(1,078)(1,177)

Comprehensive Income ($ in thousands)

11/30/2020
Q1
8/31/2020
Q4
5/31/2020
Q3
2/29/2020
Q2
11/30/2019
Q1
8/31/2019
Q4
5/31/2019
Q3
Net loss:(710)(676)(1,391)(997)(925)(1,116)(1,188)
Other undisclosed comprehensive income     14 
Comprehensive loss:(710)(676)(1,391)(997)(925)(1,102)(1,188)
Comprehensive loss, net of tax, attributable to noncontrolling interest(14)(94)  (17)(38)(16)
Comprehensive loss, net of tax, attributable to parent:(724)(770)(1,391)(997)(942)(1,139)(1,204)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: